NovoCure

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. 

CEO
Frank Leonard
CEOFrank Leonard
Employees
1,605
Employees1,605
Headquarters
St. Helier, Jersey
HeadquartersSt. Helier, Jersey
Founded
2000
Founded2000
Employees
1,605
Employees1,605

NVCR Key Statistics

Market cap
1.20B
Market cap1.20B
Price-Earnings ratio
-8.63
Price-Earnings ratio-8.63
Dividend yield
Dividend yield
Average volume
1.26M
Average volume1.26M
High today
$10.87
High today$10.87
Low today
$10.30
Low today$10.30
Open price
$10.52
Open price$10.52
Volume
1.15M
Volume1.15M
52 Week high
$20.06
52 Week high$20.06
52 Week low
$9.82
52 Week low$9.82

Stock Snapshot

The current NovoCure(NVCR) stock price is $10.75, with a market capitalization of 1.2B. The stock trades at a price-to-earnings (P/E) ratio of -8.63.

As of 2026-04-03, NovoCure(NVCR) stock has fluctuated between $10.30 and $10.87. The current price stands at $10.75, placing the stock +4.4% above today's low and -1.1% off the high.

The NovoCure(NVCR)'s current trading volume is 1.15M, compared to an average daily volume of 1.26M.

During the past year, NovoCure(NVCR) stock moved between $9.82 at its lowest and $20.06 at its peak.

During the past year, NovoCure(NVCR) stock moved between $9.82 at its lowest and $20.06 at its peak.

NVCR News

Simply Wall St 5h
NovoCure Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer

In late March 2026, Novocure reported that its Phase 2 PANOVA-4 trial showed Tumor Treating Fields therapy combined with atezolizumab and gemcitabine/nab-paclit...

NovoCure Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer
Simply Wall St 5d
A Look At NovoCure Valuation After Extended Share Price Weakness

Advertisement NovoCure stock moves after recent performance shifts NovoCure (NVCR) is back on many investors’ screens after a recent stretch of weaker share p...

A Look At NovoCure Valuation After Extended Share Price Weakness

Analyst ratings

75%

of 8 ratings
Buy
75%
Hold
25%
Sell
0%

People also own

Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.